Elranatamab:

Disha Kakkar1, Aakanksha Singh1, Reshmi Harikumar Pillai1

  • 1Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India.

PubMed
概括

埃拉拉纳塔马布单疗法在印度复发/耐药多发性骨髓瘤患者中显示出前景. 现实世界的数据突出了疗效,但也有诸如细胞因子释放综合征和神经毒性等风险,需要仔细监测.